Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Dilacor XR Extended Release Capsules

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

54 API Suppliers, 21 USDMF, 8 CEP/COS, 5 JDMF, 6 EU WC, 6 KDMF, 16 NDC API, 25 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

13 Drugs in Development

13 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

395 FDF Dossiers, 238 FDA Orange Book, 40 Europe, 84 Canada, 7 South Africa, 26 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 120MG, TABLET;ORAL - 30MG, TABLET;ORAL - 60MG, TABLET;ORAL - 90MG, CAPSULE, EXTENDED RELEASE;ORAL - 120MG, CAPSULE, EXTENDED RELEASE;ORAL - 180MG, CAPSULE, EXTENDED RELEASE;ORAL - 240MG, CAPSULE, EXTENDED RELEASE;ORAL - 300MG, CAPSULE, EXTENDED RELEASE;ORAL - 360MG, CAPSULE, EXTENDED RELEASE;ORAL - 120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 180MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 240MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 120MG, CAPSULE, EXTENDED RELEASE;ORAL - 180MG, CAPSULE, EXTENDED RELEASE;ORAL - 240MG, CAPSULE, EXTENDED RELEASE;ORAL - 300MG, CAPSULE, EXTENDED RELEASE;ORAL - 360MG, CAPSULE, EXTENDED RELEASE;ORAL - 420MG, TABLET, EXTENDED RELEASE;ORAL - 120MG, TABLET, EXTENDED RELEASE;ORAL - 180MG, TABLET, EXTENDED RELEASE;ORAL - 240MG, TABLET, EXTENDED RELEASE;ORAL - 300MG, TABLET, EXTENDED RELEASE;ORAL - 360MG, TABLET, EXTENDED RELEASE;ORAL - 420MG

RELATED EXCIPIENT COMPANIES

14 Evonik, 3 Rochem International Inc, 20 SPI Pharma, 13 DKSH, 6 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 7 Kirsch Pharma, 4 ACG Worldwide, 10 Actylis, 1 Aeon Procare, 2 Alcedo Pharmachem, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 32 BASF, 1 CD Formulation, 22 Corel Pharma Chem, 5 DFE Pharma, 1 Esteem Industries, 2 Finar, 11 Gangwal Chemicals, 12 Ideal Cures, 4 Ingredion Pharma Solutions, 20 Kerry, 3 Keval Exports, 5 Kima Chemical, 6 Lonza Capsugel, 19 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 8 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 33 Roquette, 14 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 Silverline Chemicals, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 2 Valens Pharmachem, 3 Vasa Pharmachem, 3 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

88 Fillers, Diluents & Binders, 75 Coating Systems & Additives, 57 Controlled & Modified Release, 45 Thickeners and Stabilizers, 40 Solubilizers, 36 Direct Compression, 33 Granulation, 31 Taste Masking, 28 Film Formers & Plasticizers, 24 Parenteral, 23 Disintegrants & Superdisintegrants, 20 Lubricants & Glidants, 19 Chewable & Orodispersible Aids, 17 Topical, 16 Co-Processed Excipients, 11 Rheology Modifiers, 11 Emulsifying Agents, 9 Empty Capsules, 6 API Stability Enhancers, 5 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

38 News #PharmaBuzz

38 News #PharmaBuzz

GLOBAL SALES INFORMATION

41 US Medicaid Prescriptions, 57 Regulatory FDF Prices, 1 Annual Reports

MARKET PLACE

13 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

25 Health Canada Patents

25 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 2 Others

ANALYTICAL

2 Analytical Methods

2 Analytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	TAPI Technology & API Services	Israel	Korea Unipharm Co., Ltd.	20200302-209-J-279	Diltiazem hydrochloride	2020-03-02	Teva API India Private Limited	India	Plot Nos. A-2, A-2/1, A-2/2, UPSIDC Industrial Area, Bijnor Road, Gajraula-244 235, Distt. Amroha (Uttar Pradesh) India
29/11/2025	Cambrex Corporation	U.S.A	Samoh Pharmaceutical Co., Ltd.	20220801-209-J-1292	Diltiazem hydrochloride	2022-08-01	Cambrex Profarmaco Milano Srl	Italy	Via Curiel, 34 – 20067 Paullo (Milan) Italy

Dilacor XR Extended Release Capsules

Dilacor XR Extended Release Capsules

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

54 API Suppliers

21 USDMF

8 CEP/COS

5 JDMF

6 EU WC

6 KDMF

16 NDC API

25 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

13 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

395 FDF Dossiers

238 FDA Orange Book

40 Europe

84 Canada

7 South Africa

26 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 120MG

TABLET;ORAL - 30MG

TABLET;ORAL - 60MG

TABLET;ORAL - 90MG

CAPSULE, EXTENDED RELEASE;ORAL - 120MG

CAPSULE, EXTENDED RELEASE;ORAL - 180MG

CAPSULE, EXTENDED RELEASE;ORAL - 240MG

CAPSULE, EXTENDED RELEASE;ORAL - 300MG

CAPSULE, EXTENDED RELEASE;ORAL - 360MG

CAPSULE, EXTENDED RELEASE;ORAL - 120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE, EXTENDED RELEASE;ORAL - 180MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE, EXTENDED RELEASE;ORAL - 240MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE, EXTENDED RELEASE;ORAL - 120MG

CAPSULE, EXTENDED RELEASE;ORAL - 180MG

CAPSULE, EXTENDED RELEASE;ORAL - 240MG

CAPSULE, EXTENDED RELEASE;ORAL - 300MG

CAPSULE, EXTENDED RELEASE;ORAL - 360MG

CAPSULE, EXTENDED RELEASE;ORAL - 420MG

TABLET, EXTENDED RELEASE;ORAL - 120MG

TABLET, EXTENDED RELEASE;ORAL - 180MG

TABLET, EXTENDED RELEASE;ORAL - 240MG

TABLET, EXTENDED RELEASE;ORAL - 300MG

TABLET, EXTENDED RELEASE;ORAL - 360MG

TABLET, EXTENDED RELEASE;ORAL - 420MG

RELATED EXCIPIENT COMPANIES

14 Evonik

3 Rochem International Inc

20 SPI Pharma

13 DKSH

6 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

2 Pfanstiehl

7 Kirsch Pharma

4 ACG Worldwide

10 Actylis

1 Aeon Procare

2 Alcedo Pharmachem

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

32 BASF

1 CD Formulation

22 Corel Pharma Chem

5 DFE Pharma

1 Esteem Industries

2 Finar

11 Gangwal Chemicals

12 Ideal Cures

4 Ingredion Pharma Solutions

20 Kerry

3 Keval Exports

5 Kima Chemical

CAPSULE, EXTENDED RELEASE;ORAL - 120MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE, EXTENDED RELEASE;ORAL - 180MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE, EXTENDED RELEASE;ORAL - 240MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons